Antibiotics as deep modulators of gut microbiota: between good and evil. (Q36105508)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531828%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

review article

1 reference

title

Antibiotics as deep modulators of gut microbiota: between good and evil (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531828%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531828%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Herbert Tilg

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531828%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Antonio Gasbarrini

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531828%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

English

0 references

publication date

16 August 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531828%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531828%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531828%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531828%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

1906-1915

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531828%20AND%20SRC:MED&resulttype=core&format=json

A metagenomic insight into our gut's microbiome

21 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The microbiome revolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Antibiotic use and its consequences for the normal microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Effect of antimicrobial agents on the ecological balance of human microflora

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Colonization dynamics of ampicillin-resistant Escherichia coli in the infantile colonic microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The gut microbiota--masters of host development and physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The human gut microbiota and virome: Potential therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Role of yeasts in healthy and impaired gut microbiota: the gut mycome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The first 1000 cultured species of the human gastrointestinal microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Enterotypes of the human gut microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Micro-eukaryotic diversity of the human distal gut microbiota: qualitative assessment using culture-dependent and -independent analysis of faeces.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Uncovering effects of antibiotics on the host and microbiota using transkingdom gene networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Long-term impacts of antibiotic exposure on the human intestinal microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Determining the Long-term Effect of Antibiotic Administration on the Human Normal Intestinal Microbiota Using Culture and Pyrosequencing Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Long-term ecological impacts of antibiotic administration on the human intestinal microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Routine Amoxicillin for Uncomplicated Severe Acute Malnutrition in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Effects of β-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to Clostridium difficile associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Impact of Prematurity and Perinatal Antibiotics on the Developing Intestinal Microbiota: A Functional Inference Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon-like peptide 1 in diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Antibiotic administration routes significantly influence the levels of antibiotic resistance in gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

High-level colonisation of the human gut by Verrucomicrobia following broad-spectrum antibiotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Amoxicillin treatment modifies the composition of Bifidobacterium species in infant intestinal microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Influence of antibiotic exposure in the early postnatal period on the development of intestinal microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Intestinal microbiota of 6-week-old infants across Europe: geographic influence beyond delivery mode, breast-feeding, and antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of Enterobacter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The initial state of the human gut microbiome determines its reshaping by antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Composition and temporal stability of the gut microbiota in older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Burden of Clostridium difficile infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The economic burden of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Comorbidities, Exposure to Medications, and the Risk of Community-Acquired Clostridium difficile Infection: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Toxin synthesis by Clostridium difficile is regulated through quorum signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Bile salts and glycine as cogerminants for Clostridium difficile spores

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Duodenal infusion of donor feces for recurrent Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Luminal sulfide and large intestine mucosa: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Phylogenetic analysis of dysbiosis in ulcerative colitis during remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Low counts of Faecalibacterium prausnitzii in colitis microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Disease-specific alterations in the enteric virome in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The treatment-naive microbiome in new-onset Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Guidelines for the management of inflammatory bowel disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Abnormal breath testing in IBS: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Use and abuse of hydrogen breath tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Therapeutic modulation of gut microbiota: current clinical applications and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The networks of human gut microbe-metabolite associations are different between health and irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Intestinal microbiota in functional bowel disorders: a Rome foundation report

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Non-enteric infections, antibiotic use, and risk of development of functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Antibiotic treatment of constipation-predominant irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Obesity alters gut microbial ecology

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Microbial ecology: human gut microbes associated with obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Human colonic microbiota associated with diet, obesity and weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Richness of human gut microbiome correlates with metabolic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

High-fat diet determines the composition of the murine gut microbiome independently of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

A metagenome-wide association study of gut microbiota in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Gut metagenome in European women with normal, impaired and diabetic glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Microbiota and diabetes: an evolving relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Why and how antibiotics are used in swine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Antibiotics in early life and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Antibiotics in early life alter the murine colonic microbiome and adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Altering the Intestinal Microbiota during a Critical Developmental Window Has Lasting Metabolic Consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Modulation of gut microbiota by antibiotics improves insulin signalling in high-fat fed mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Association of antibiotics in infancy with early childhood obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Administration of Antibiotics to Children Before Age 2 Years Increases Risk for Childhood Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Risk Factors for Childhood Obesity in the First 1,000 Days: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Antibiotic Exposure During the First 6 Months of Life and Weight Gain During Childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Prenatal exposure to antibiotics, cesarean section and risk of childhood obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Effect of long-term antibiotic use on weight in adolescents with acne

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The effect of past antibiotic exposure on diabetes risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Antibiotics in fetal and early life and subsequent childhood asthma: nationwide population based study with sibling analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Early-life antibiotic use is associated with wheezing among children with high atopic risk: a prospective European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Association Between Antibiotic Exposure, Bronchiolitis, and TLR4 (rs1927911) Polymorphisms in Childhood Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Intestinal microbiota in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Colonic microbiome is altered in alcoholism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Altered intestinal microbiota as a major driving force in alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Characterization of fecal microbial communities in patients with liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Alterations of the human gut microbiome in liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Linkage of gut microbiome with cognition in hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Treatment of hepatic encephalopathy with metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Rifaximin treatment in hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

Gut microbiota disturbance during antibiotic therapy: a multi-omic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-312297

10.1136/GUTJNL-2016-312297

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531828%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference